Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis blockbuster slate boosts partners' stock

This article was originally published in Scrip

Executive Summary

The UK firm Vernalis saw its share price rise by 10% to 42.36 pence after Novartis included its novel heat shock protein 90 (HSP90) inhibitor AUY922 in a list of seven potential blockbusters in its pipeline, even though the first planned submission is not slated to take place until 2015 or later.

You may also be interested in...



Pfizer, Fosun Partner BioNTech On mRNA COVID-19 Vaccine

BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.

CureVac’s German Owner Rejects US Coronavirus Vaccine Grab

Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.

Buyers And Sellers: How Corporate Transactions Are Shaping Pharma

Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.

Topics

Related Companies

UsernamePublicRestriction

Register

SC013762

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel